Biomed is focused on novel drugs that show efficacy and safety for the treatment of neurodegenerative diseases.
The management team is led by Lloyd L. Tran, CEO and Chairman. Lloyd has been a research scientist, with 30 years in drug discovery for major pharmaceutical companies including Monsanto and Pfizer.
Lloyd was the drug developer of Artemether for the treatment of malaria in early 1990's in collaboration with a Chinese research team. He coordinated the clinical trials of Artemether gel capsule with the World Health Organization (WHO) and Walter Reed Army Institute of Research (WRAIR) that lead to its approval in over 80 countries worldwide, including the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).
With the founding of Biomed Industries, Lloyd turned his attention to solving unmet needs for CNS diseases. Based on the discovery that in Alzheimer's patients the ability to regenerate new neurons in the hippocampus is impaired, causing memory loss and cognitive impairment, Lloyd and team developed NA-831. This drug facilitates Neurogenesis, restoring memory loss and improving cognitive functions. Phase 2A clinical data of NA-831 has shown proof of safety and efficacy for patients with mild and moderate Alzheimer's disease. The Company will conduct Phase 2B and Phase 3 trials for the treatment and prevention of Alzheimer's disease.
Biomed is one the leading pioneers researching this new Neurogenesis approach to solve the challenges in Alzheimer's disease as well as other neurodegenerative and CNS-related diseases.
The drug NA-831™ is a small molecule drug that is administered orally. NA-831 easily crosses the blood-brain barrier and exhibits neuroprotection to mitigate further damage. The drug exhibits strong neurogenesis, i.e., the ability to generate new neurons.
In a Phase 2A Randomized Double-Blind Placebo-Controlled Phase 2A Clinical Trial of Patients with MCI and Mild and Moderate Alzheimer's Disease, NA-831 was well-tolerated with no adverse events or concerning safety signals. In addition, there was a significant improvement in memory test performance for the Alzheimer's patients in the study who were administered NA-831 compared to placebo.
NA-831 showed a significant improvement for patients with mild and moderate AD with the ADAS-Cog score changed of an average of 4.1 as compared to the placebo after 24 weeks of treatment. The Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-Plus) showed 82.1% patients improved.
The clinical results of the Phase 1 and Phase 2 clinical trials of NA-831 have been presented at various international conferences mentioned above. The Phase 3 clinical trials of NA-831 has been scheduled to evaluate its safety and efficacy as required by the US Food and Drug Administration (FDA) and other regulators overseas before being approved for usage and marketing worldwide.
Vineurocin (NA704) can modulate the aging process in humans. NA-704 regulates cell growth and development, especially in nerve cells, as well as cellular DNA synthesis.
NA-704™ exhibits neuroprotection and neurogenesis, demonstrating strong potential for the treatment of Alzheimer's disease and other neurological disorders. NA-704 is to be administered intravenously once a week, per prescription of a qualified physician.
WE NEED NAMES FOR THE DRUGS TARGETING MDD, RETT, FRAGILE X, AND OBESITY. LIST THEM HERE WITH A BRIEF PARAGRAPH
The Company has also developed and commercialized an FDA-approved disposable infusion system designed for the intravenous administration of injectable drugs. There are more than 100 injectable drugs that can be used with the MICROS for treatment of infectious diseases, cancer chemotherapy and cardiovascular diseases and neurological diseases.
The MICROS can be prefilled with NA-704 for controlled release of the injectable medication for treatment of Alzheimer's disease and Multiple Sclerosis.
The NA-704/MICROS infusion system offers an accurate intravenous dosage and is ready to be administered to the patient in a convenient and comfortable setting at home.
For more information about the MICROS™ Infusion System, please Contact Us